like receptors (TLRs). Typical highly endotoxic LPS are recognized by the TLR4/MD2/CD14 complex, whereas the TLR that recognizes the weakly exdotoxic H. pylori LPS is controversial as discussed below. Bacterial flagella also act as a PAMP, and they are recognized by TLR5. Like the LPS, H. pylori flagella also show less activity as a TLR5 agonist (Andersen-Nissen et al., 2005) . The PAMPs of H. pylori, therefore, share low potency as TLR agonists, namely they are weak inducers of inflammation. In addition to low endotoxic activity, H. pylori LPS has several unique features, for example structures that mimic host Lewis blood group antigens (Moran, 2008) . In this review, the chemical characteristics, biological activities, and role in gastric carcinogenesis of H. pylori LPS will be described. In particular we will focus on our recent research into LPS as a pathogenic factor for carcinogenesis.
General architecture of H. pylori LPS
Like other typical bacterial LPS, H. pylori LPS consists of three region, namely lipid A, core oligosaccharide and O-polysaccharide (Fig. 1 ). The weakly endotoxic activity is due to the chemical structure of lipid A portion. In H. pylori LPS, the carbohydrate portion of lipid A consists of a glucosaminyl-β-1-6-glucosamine disaccharide backbone, as well as the typical lipid A. Whereas the lipid A of typical LPS derived from E. coli contains six fatty acid residues with relatively short carbon chain, such as C14 and C12, H. pylori lipid A contains three to five fatty acids with long carbon chain of C18 and C16 (Moran et al., 1997; Suda et al., 1997) . Netea et al. (2002) describe that the molecular shapes, such as conical, cylindrical and intermediate, of lipid A are different between the highly endotoxic typical LPS and the weakly endotoxic LPS. The diversity of molecular shapes may cause the difference of endotoxic activity and usage of TLRs. Remodeling of lipid A structures occur in H. pylori by the action of phosphatase, ethanolamine phosphate transferase, 3-deoxy-D-mannooctulosonic acid (KDO) hydrolase and deacylase (Tran et al., 2005) . Hildebrandt & McGee (2009) report structural modifications of lipid A occur in an exogenous cholesteroldependent manner. Thus lipid A structures may vary among strains or change depending on culture conditions. The core oligosaccharide region of H. pylori LPS has a characteristic structure among H. pylori strains, however, the detailed structure is distinct from the typical LPS (Aspinall et al., 1997; Monteiro, 2001) . It contains KDO and heptose residues similar to typical gramnegative bacterial LPS. There is some heterogeneity among H. pylori strains. For example, heptose oligomer (heptan) or glucose oligomer (glucan) is found in some strains. One of the important features of H. pylori LPS is the O-polysaccharide region that bears the mimicking structures of the host carbohydrate antigens, Lewis antigens (Moran, 2008) . It is interesting that Campylobacter species, which also belongs to spirillum, also shares host carbohydrate structures in gangliosides, such as GM1 and GQ1b (Yuki, 1999) . Host Lewis antigens are recognized as a tumor antigen. Le x is also known as CD15, which is a marker for neutrophils. The existence of Lewis antigens, such as Le x , Le y , Le a and Le b , varies among H. pylori strains. Lewis antigns are considered to contribute to escape from a host immune response and to induction of an autoimmune response. The O-polysaccharide of most H. pylori strains consists of a lactosamine (galacotosyl-β1-4-N-acetyl-glucosamine) unit as the backbone chain. L-Fucose residues are partially substituted in the backbone chain and form a polymeric Le x structure. In addition, a high level of variability occurs in the non-reducing terminal end of the O-polysaccharide chain. For example, β1-3-or β1-4-linked galactose and α1-3-or α1-4-linked fucose can substitute on the N-acetyl-glucosamine residue, and α1-2-linked fucose can occur on the galactose residue. The variable substitutions form various Lewis antigen structures (Fig. 2) . 
Biological roles of Lewis antigens H. pylori LPS
As described above, H. pylori Lewis antigens mimic host antigens and can thus modulate various host physiological responses, especially immunological reactions. The O-polysaccharide, in particular the polymeric Le x structure, has been shown to contribute to adhesion of H. pylori to human antral gastric mucosa. Galectin-3 is a gastric receptor for H. pylori Le x antigen (Fowler et al., 2006 (Bergman et al., 2004) . The other C-type lectin that interact with H. pylori LPS is surfactant protein D (SP-D) (Khamri et al., 2005; Murray et al., 2002) . SP-D is involved in antibodyindependent clearance of bacteria. Levels of SP-D are increased in gastric mucosa with H. pylori-associated antral gastritis compared to normal gastric mucosa. The fucose residues of the O-polysaccharide chain are shown to be important for the recognition of SP-D. On the other hand, our recent study showed that D-galactose residue of H. pylori LPS is involved in interaction with SP-D as described below. Another important issue is formation of anti-Lewis antigen autoantibodies. Anti-Le y autoantibodies have been implicated in the pathogenesis of atrophic gastritis. The anti-Le y autoantiboides are found both in patients with atrophic gastritis and gastric cancer (Heneghan et al., 2001; Negrini et al., 1996) . A candidate for the target of the autoantibodies is the β-chain of the H + ,K + -ATPase, which is a proton pump . AntiLe x autoantibodies are also found in H. pylori-infected patients (Heneghan et al., 2001; Negrini et al., 1996) . Anti-Le x antibodies have been shown to activate neutrophils and enhance their adhesion to endothelium (Stockl et al., 1993) which could lead to inflammation and tissue damage. However, these antibodies induced by H. pylori do not react with synthetic Lewis antigens Heneghan et al., 2001 ). The actual specificity of the anti-Lewis antigen antibodies has not been clear yet.
Antigenic epitopes of H. pylori LPS
Whereas anti-Lewis antigen autoantibodies have been shown to be raised in response to H. pylori infection and to contribute to generation of diseases, we did not found significantly increased levels of any anti-Lewis antigen antibodies in H. pylori-infected gastroduodenal disease patients, H. pylori-positive individuals, and H. pylori-negative individuals . The reactivity of human antisera to H. pylori LPS derived from various strains was examined and a classification of H. pylori LPS has been proposed based on the antigenicity of O-polysaccharides to humans, namely highly-antigenic-epitope-carrying LPS and weakly-antigenic-epitope-carrying LPS Yokota et al., 2000b) . The two epitopes were clearly characterized by examining serum absorption by LPS (Fig. 3) . All H. pylori strains carrying the O-polysaccharide chain (namely, smooth strains) isolated in Japan have either one or the other epitope, but not both. The existence of these epitopes does not relate to that of the Lewis antigen structures. Most (over 95%) of H. pylori-infected individuals, including gastroduodenal patients and asymptomatic individuals, have a high titer of antibodies against the anti-highly-antigenic epitope in their sera. It is therefore proposed that the highly-antigenic epitope-carrying LPS are applicable to diagnosis of H. pylori infection (Table 1) . As an advantage, the LPS antigen is more stable against heat, drying and humidity than protein antigens. On the other hand, about half of H. pylori-infected individuals have antibodies against the weakly-antigenic epitope at a lower titer than those against the highly-antigenic epitope. The antibody titer against the weakly-antigenic epitope is significantly higher in gastroduodenal patients than in asymptomatic individuals with H. pylori infection (Yokota et al., 2000a Serum from one individual containing antibodies against both epitopes was absorbed with the indicated LPS at 37 C for 1 h, and used in Western blotting. LPS derived from strains GU2 and DU2 are highly-antigenic epitope-containing. LPS derived from strains CA2 and CA6 are weakly-antigenic epitope-containing.
Usage of TLRs by H. pylori LPS
TLR usage by H. pylori LPS remains controversial. An important issue to consider in these kinds of studies is the presence of contaminants with endotoxin-like activities, for example lipopeptides of H. pylori and other bacterial LPS, in the H. pylori LPS preparations. The extremely low level activity of H. pylori LPS means that very low level contamination cannot be ignored. Alternatively, as described above, structural heterogeneity exists in H. pylori lipid A and therefore different TLR usage could depend on lipid A structural variation. Whereas the weakly endotoxic activity of H. pylori LPS is widely accepted, TLR usage has been controversial with some researchers reporting that H. pylori LPS transduces signaling via the TLR4/MD2/CD14 complex like a typical LPS and others reporting signaling transduction via TLR2 as summarized in Table 2 . Another report describes antagonistic activity of H. pylori LPS derived from some strains to TLR4-mediated typical LPS signaling (Lepper et al., 2005) . Strains having the highly-antigenic epitope-carrying LPS are frequently found in those derived from patients with chronic gastritis. Strains having the weakly-antigenic epitopecarrying LPS are predominantly found in those derived from patients with gastric cancer (Yokota et al., 2000b; Yokota et al., 1997) (Fig. 4 ). 
Novel biological activities of H. pylori LPS
While a consensus has gotten on that H. pylori LPS share low toxicity as an endotoxin, some important biological activities have been observed. Chochi et al. (2008) reported that both H. pylori and E. coli LPS enhance the proliferation rate of gastric cancer cell lines. However, they also showed that H. pylori LPS, but not E. coli LPS, attenuates the cytotoxicity of mononuclear cells against gastric cancer cells, and downregulates perforin production in CD56 + natural killer cells cocultured with gastric cancer cells. Both the mitogenic activity, in common with E. coli, and the H. pylori-specific decrease in cytotoxicity of natural killer cells are likely to promote tumorigenesis. Grebowska et al. report that H. pylori LPS suppress phagocytic activity of human peripheral blood granulocytes (Grebowska et al., 2008) and H. pylori LPS-chased macrophages have low activity of lymphocyte proliferation (Grebowska et al., 2010) . They speculate that these activities contribute to chronic infection of H pylori. Slomiany et al. reported that H. pylori LPS disrupts gastric mucin synthesis, increases caspase-3 activity, causes apoptosis, and upregulates endothelin-1 and TNF-α via p38 and ERK MAP kinase cascade activation (Slomiany et al., 1999; Slomiany & Slomiany, 2002) . Furthermore, it inhibits glycation and sulfation in gastric mucin biosynthesis (Slomiany et al., 1992) . Kawahara et al. (2001) reported that the LPS of H. pylori, as well as that of E. coli, upregulates mitogen oxidase 1 (Mox1), which leads to the generation of superoxide anions. Young et al. (1992) report that it stimulates gastric mucosal pepsinogen secretion. These are likely to lead to injury of gastric mucosa. We found that pretreatment of gastric epithelial cell lines with H. pylori LPS enhanced the expression of TLR4 and also the responsiveness to E. coli LPS (Fig. 5-C) (Yokota et al., 2010) . These gastric epithelial cell lines express markedly low levels of TLR4. H. pylori LPS www.intechopen.com Gastric cancer cell line MKN28 was treated with H. pylori LPS (100 ng/ml) for 24 h, then treated with E. coli LPS (1000 ng/ml) for 24 h, and IL-8 in the culture supernatants was measured by ELISA. LPS derived from GU2 and DU2 H. pylori strains is highly-antigenic epitope-carrying. LPS derived from CA2 and CA6 strains is weakly-antigenic LPS-carrying. LPS derived from CG10 strain is rough-type. B. TLR4 promoter activity with H. pylori CA2 LPS treatment determined by the luciferase reporter assay. Luciferase gene-conjugated promoters with a series of mutations introduced in the transcription factor binding motifs indicated were used. NF-Y binding motif is indicated to be important for transcriptional induction of TLR4 by H. pylori LPS. C. Enhancement of TLR4 expression by H. pylori LPS and effect of inhibitors for MAP kinases. MKN28 cells were treated with H. pylori CA2 LPS (100 ng/ml) for 24 h, and then TLR4 on the cell surface was analyzed by flow cytometry. D. Enhancement of gastric epithelial cell growth by H. pylori LPS and effect of MAP kinase inhibitors. MKN28 cells were treated with H. pylori CA2 LPS (100 ng/ml) for 18 h, and then cell proliferation rate was measured by the uptake of 5-ethinyl-2'-deoxyuridine into DNA. MAP kinase inhibitors used were PD98059 (MEK1/2 inhibitor; 50 μM), FR180204 (ERK1/2 inhibitor; 5 μM), SB202190 (p38 inhibitor; 5 μM), and SP600125 (JNK inhibitor; 10 μM).
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Fig. 6. Proposed action of H. pylori LPS on gastric epithelial cells.
H. pylori LPS upregulates TLR4 and augments cell proliferation via TLR2 and the MEK1/2-ERK1/2 MAP kinase pathway in gastric epithelial cells. These activities are likely to enhance the inflammatory response, by increasing the activity of highly endotoxic typical LPS derived from other bacteria, and tumorigenesis.
recognized by TLR2, preferentially as a TLR2/TLR1 complex, activated MEK-ERK MAP kinase cascade and the transcription factor NF-Y, and upregulated transcription of the TLR4 gene ( Fig. 5-B ). In consistent with the in vitro observation, Asahi et al. (2007) indicate that higher expression of TLR4 is observed in biopsy specimens in the antral and corpus mucosa from H. pylori-infected patients than H. pylori-negative individuals. Backhed et al. (2003) report that primary gastric antral cells do not express TLR4, in contrast, several epithelial cell lines derived form gastric cancer do. The upregulated TLR4 in the gastric epithelial cells causes more efficient transduction of inflammatory signals by typical LPS, such as LPS derived from Enterobacteriaceae ( Fig. 5-A) .
In concordance with the report of Chochi et al. (2008) , H. pylori LPS was shown to upregulate the cell growth rate of gastric epithelial cell lines (Yokota et al., 2010) (Fig. 5-D) . Activation of the MEK-ERK MAP kinase pathway via TLR2 activates NF-Y, and the NF-Y transcriptionally activates various cell cycle regulation genes, such as cyclin A1, cyclin B2, and E2F1. However, there are some contradictions between our report (Yokota et al., 2010) and the report of Chochi et al. (2008) . We found that the mitogenic activity was H. pylorispecific. With respect to TLR usage, Chochi et al. (2008) showed that anti-TLR4 antibody can neutralize the activity; however, we found that downregulation of TLR2 expression by siRNA diminished the activity (Yokota et al., 2010 ). The novel activities of H. pylori LPS reported by us (Yokota et al., 2010) (Fig. 6) (Yokota et al. unpublished results) . SP-D interacts more strongly with weakly-antigenic epitope-carrying LPS than highlyantigenic epitope-carrying LPS. The β-linked N-acetyl-glucosamine residue is suggested to be important for the highly-antigenic epitope, and digestion of the residue by a β-N-acetylglucosamindase abolished the reactivity with anti-highly antigenic epitope antibody and appeared reactivity with anti-weakly antigenic epiotpe antibodies (Yokota et al., unpublished results) . The β-galacotose residue is implicated in the weakly antigenic epitope and interaction with SP-D.
Concluding remarks
We propose the existence of two antigenic epitopes in H. pylori LPS. One of these, the weakly-antigenic epiotpe-carrying LPS, appears to occur frequently in strains derived from gastric cancer patients, as compared with chronic gastritis patients. The anti-weaklyantigenic epitope antibody titers are higher in gastroduodenal patients than in asymptomatic H. pylori-infected individuals. The weakly-antigenic epitope-carrying LPS has stronger biological activity than the highly-antigenic epitope-carrying LPS. From these lines of evidence, strains carrying highly-antigenic epitope may change to strains carrying weakly-antigenic epitope during infection periods and disease progression status (Fig. 7) . This phenotypic change leads to an escape strategy for H. pylori from host immune response www.intechopen.com
